News

Abdera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13

Abdera Therapeutics Presents Initial Phase 1 Clinical Data on ABD-147, a Next-generation DLL3-targeting Radiopharmaceutical Therapy, at IASLC 2025 World Conference on Lung Cancer

Abdera Therapeutics to Present Early Pharmacokinetics, Dosimetry and Safety Data from Ongoing Phase 1 Trial of ABD-147 at the IASLC 2025 World Conference on Lung Cancer and Participate in Upcoming Investor Conferences

Abdera Therapeutics Appoints Rachael Brake, Ph.D., as Chief Scientific Officer

Abdera Therapeutics to Present Key Updates on its Radiopharmaceutical Development Pipeline at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Abdera Therapeutics to Present at the 43rd Annual J.P Morgan Healthcare Conference

Abdera Therapeutics Announces FDA Orphan Drug Designation for ABD-147 for the Treatment of Neuroendocrine Carcinoma

Fierce Biotech Names Abdera Therapeutics a “Fierce 15” Biotech Company of 2024

Abdera Therapeutics Announces FDA Fast Track Designation for ABD-147, a Next-Generation Precision Radiopharmaceutical Therapy, for the Treatment of Patients with Extensive-stage Small Cell Lung Cancer

Abdera Therapeutics Announces FDA Clearance of IND Application for ABD-147